ArticleMolecular diagnosis & therapy2015
MicroRNA-21 Expression in Primary Breast Cancer Tissue Among Egyptian Female Patients and its Correlation with Chromosome 17 Aneusomy.
Article in Molecular diagnosis & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 11 citations in OpenAlex.
- Comparison of the diagnostic power of serum circulating miR-21, VEGF, and CA15-3 in breast cancer.Frontiers in oncology · 2026Article
- Genomic landscapes of breast cancer in African populations: a systematic review.NPJ breast cancer · 2025Review
- Exploring research progress in studying serum exosomal miRNA-21 as a molecular diagnostic marker for breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Interrelation of the Circulating and Tissue MicroRNA-21 with Tissue PDCD4 Expression and the Invasiveness of Iraqi Female Breast Tumors.Indian journal of clinical biochemistry : IJCB · 2019Article
- MiR-328 May be Considered as an Oncogene in Human Invasive Breast Carcinoma.Iranian Red Crescent medical journal · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBreast cancer (BC) is the most common cancer amongst Egyptian women and worldwide. MicroRNA-21 (miR-21), on chromosome 17q21.3, is one of the most up-regulated microRNAs in cancer that silences multiple target genes involved in cancer-signaling pathways. The aim of this study was to assess the correlation between numerical aberrations of chromosome 17 and the miR-21 expression profile in BC tissues in female Egyptian patients.
methodsThe study included 37 female patients with sporadic primary breast carcinoma, their age ranged from 31 to 65 years. Fresh breast tissue specimens were evaluated for miR-21 expression levels using reverse transcription-polymerase chain reaction technology and cytogenetic fluorescent in situ hybridization analysis for chromosome 17 aneusomy.
resultsmiR-21 was up-regulated 12.9-fold in BC tissues compared with normal adjacent tissue. Over-expression was significantly associated with several clinico-pathologic characteristics; as higher tumor grade, more tumor size, advanced stage, and poor prognostic index. In addition, chromosome 17 monosomy and trisomy were observed in 21.6 and 5.4 % of BC patients, respectively. However, the large majority (73 %) of patients had heterogeneous cell populations. Chromosome 17 copy number heterogeneity in cell populations were significantly associated with advanced clinical stage and higher miR-21 expression profile in BC tissues.
conclusionChromosome 17 aneusomy and miR-21 expression are positively correlated and can potentially serve as prognostic markers in BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.